{"id":"agalsidase-alfa","rwe":[{"pmid":"41607773","year":"2025","title":"A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"},{"pmid":"41377851","year":"2025","title":"Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis.","finding":"","journal":"Clinical kidney journal","studyType":"Clinical Study"},{"pmid":"41313298","year":"2026","title":"Long-Term Cardiac Stability Despite Late Enzyme Replacement Therapy in Fabry Disease With Severe Renal Involvement.","finding":"","journal":"JACC. Case reports","studyType":"Clinical Study"},{"pmid":"41196191","year":"2026","title":"Long-term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey.","finding":"","journal":"European journal of clinical investigation","studyType":"Clinical Study"},{"pmid":"41013812","year":"2025","title":"Adequate hemodialysis does not compromise the cardioprotective effect of agalsidase alfa on patients with Fabry disease: a case report.","finding":"","journal":"Journal of medical case reports","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"A16AB03","category":"atc"},{"label":"Active","category":"status"},{"label":"Fabry's disease","category":"indication"}],"phase":"marketed","safety":{"safetySignals":[{"llr":45.268,"date":"","count":12,"signal":"Peritonitis","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=45)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T15:50:59.656835","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AGALSIDASE ALFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:20:45.488263+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Agalsidase Alfa","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:20:53.181178+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:21:01.795233+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:20:51.527788+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:20:45.562215+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AGALSIDASE ALFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:20:52.079375+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Globotriosylceramide hydrolytic enzyme","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:20:53.181106+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108214/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:20:52.838793+00:00"}},"allNames":"replagal","offLabel":[],"synonyms":["agalsidase alfa","replagal","agalsidase alfa (genetical recombination)"],"timeline":[{"date":"2001-08-03","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"aiSummary":"Replagal (agalsidase alfa) is a marketed enzyme replacement therapy for Fabry's disease, competing in a class with other enzyme replacements such as alglucerase, imiglucerase, agalsidase beta, laronidase, and sacrosidase. Its key strength lies in its mechanism of action, which directly addresses the deficiency of alpha-Gal A enzyme, a critical factor in managing Fabry's disease. The primary risk to Replagal is the expiration of its key composition patent in 2028, which could lead to increased competition from generic alternatives.","brandName":"Replagal","ecosystem":[{"indication":"Fabry's disease","otherDrugs":[{"name":"agalsidase beta","slug":"agalsidase-beta","company":"Genzyme"},{"name":"migalastat","slug":"migalastat","company":"Amicus Theraps Us"},{"name":"pegunigalsidase alfa","slug":"pegunigalsidase-alfa","company":"Chiesi Farmaceutici S.P.A"}],"globalPrevalence":null}],"mechanism":{"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Replagal is a recombinant human alpha-Gal A enzyme that is administered intravenously to replace the deficient enzyme in patients with Fabry's disease, thereby restoring normal globotriaosylceramide (Gb3) metabolism and reducing the accumulation of toxic intermediates."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/%CE%91-Galactosidase","title":"Α-Galactosidase","extract":"α-Galactosidase is a glycoside hydrolase enzyme that catalyses the following reaction:Hydrolysis of terminal, non-reducing α-D-galactose residues in α-D-galactosides, including galactooligosaccharides (GOS), galactomannans and galactolipids"},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5021","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AGALSIDASE%20ALFA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AGALSIDASE ALFA","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/%CE%91-Galactosidase","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:30:30.574023","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:21:01.795330+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"alglucerase","drugSlug":"alglucerase","fdaApproval":"1991-04-05","relationship":"same-class"},{"drugName":"imiglucerase","drugSlug":"imiglucerase","fdaApproval":"1994-05-23","relationship":"same-class"},{"drugName":"agalsidase beta","drugSlug":"agalsidase-beta","fdaApproval":"2003-04-24","relationship":"same-class"},{"drugName":"laronidase","drugSlug":"laronidase","fdaApproval":"2003-04-30","relationship":"same-class"},{"drugName":"sacrosidase","drugSlug":"sacrosidase","fdaApproval":"1998-04-09","relationship":"same-class"},{"drugName":"alglucosidase alfa","drugSlug":"alglucosidase-alfa","fdaApproval":"2006-04-28","relationship":"same-class"},{"drugName":"galsulfase","drugSlug":"galsulfase","fdaApproval":"2005-05-31","relationship":"same-class"},{"drugName":"idursulfase","drugSlug":"idursulfase","fdaApproval":"2006-07-24","relationship":"same-class"},{"drugName":"velaglucerase alfa","drugSlug":"velaglucerase-alfa","fdaApproval":"2010-02-26","relationship":"same-class"},{"drugName":"taliglucerase alfa","drugSlug":"taliglucerase-alfa","fdaApproval":"2012-05-01","relationship":"same-class"},{"drugName":"elosulfase alfa","drugSlug":"elosulfase-alfa","fdaApproval":"2014-02-14","relationship":"same-class"},{"drugName":"asfotase alfa","drugSlug":"asfotase-alfa","fdaApproval":"2015-10-23","relationship":"same-class"},{"drugName":"sebelipase alfa","drugSlug":"sebelipase-alfa","fdaApproval":"2015-12-08","relationship":"same-class"},{"drugName":"velmanase","drugSlug":"velmanase","fdaApproval":"2023-02-16","relationship":"same-class"},{"drugName":"cerliponase alfa","drugSlug":"cerliponase-alfa","fdaApproval":"2017-04-27","relationship":"same-class"},{"drugName":"vestronidase alfa","drugSlug":"vestronidase-alfa","fdaApproval":"2017-11-15","relationship":"same-class"},{"drugName":"pegvaliase","drugSlug":"pegvaliase","fdaApproval":"2018-05-24","relationship":"same-class"},{"drugName":"pegunigalsidase alfa","drugSlug":"pegunigalsidase-alfa","fdaApproval":"2023-05-09","relationship":"same-class"},{"drugName":"avalglucosidase alfa","drugSlug":"avalglucosidase-alfa","fdaApproval":"2021-08-06","relationship":"same-class"},{"drugName":"olipudase alfa","drugSlug":"olipudase-alfa","fdaApproval":"2022-08-31","relationship":"same-class"}],"genericName":"agalsidase alfa","indications":{"approved":[{"name":"Fabry's disease","source":"DrugCentral","snomedId":16652001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["modality→Biologic"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alglucerase","brandName":"alglucerase","genericName":"alglucerase","approvalYear":"1991","relationship":"same-class"},{"drugId":"imiglucerase","brandName":"imiglucerase","genericName":"imiglucerase","approvalYear":"1994","relationship":"same-class"},{"drugId":"agalsidase-beta","brandName":"agalsidase beta","genericName":"agalsidase beta","approvalYear":"2003","relationship":"same-class"},{"drugId":"laronidase","brandName":"laronidase","genericName":"laronidase","approvalYear":"2003","relationship":"same-class"},{"drugId":"sacrosidase","brandName":"sacrosidase","genericName":"sacrosidase","approvalYear":"1998","relationship":"same-class"},{"drugId":"alglucosidase-alfa","brandName":"alglucosidase alfa","genericName":"alglucosidase alfa","approvalYear":"2006","relationship":"same-class"},{"drugId":"galsulfase","brandName":"galsulfase","genericName":"galsulfase","approvalYear":"2005","relationship":"same-class"},{"drugId":"idursulfase","brandName":"idursulfase","genericName":"idursulfase","approvalYear":"2006","relationship":"same-class"},{"drugId":"velaglucerase-alfa","brandName":"velaglucerase alfa","genericName":"velaglucerase alfa","approvalYear":"2010","relationship":"same-class"},{"drugId":"taliglucerase-alfa","brandName":"taliglucerase alfa","genericName":"taliglucerase alfa","approvalYear":"2012","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03566017","phase":"PHASE3","title":"Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-09-16","conditions":["Fabry Disease"],"enrollment":97,"completionDate":"2025-01-21"},{"nctId":"NCT06328608","phase":"PHASE2,PHASE3","title":"A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-07-29","conditions":["Fabry Disease"],"enrollment":22,"completionDate":"2031-04"},{"nctId":"NCT05710692","phase":"PHASE2,PHASE3","title":"Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-08-01","conditions":["Fabry Disease"],"enrollment":16,"completionDate":"2029-08"},{"nctId":"NCT07465562","phase":"NA","title":"Galactol® Enzyme Supplement for Post-Prandial Abdominal Bloating in Irritable Bowel Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2026-03-16","conditions":["Irritable Bowel Syndrome","Abdominal Bloating"],"enrollment":300,"completionDate":"2026-07-31"},{"nctId":"NCT05280548","phase":"PHASE3","title":"A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-05-03","conditions":["Fabry Disease"],"enrollment":104,"completionDate":"2027-12-06"},{"nctId":"NCT00196742","phase":"","title":"Fabry Disease Registry & Pregnancy Sub-registry","status":"RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"2001-07-31","conditions":["Fabry Disease"],"enrollment":9000,"completionDate":"2034-01-31"},{"nctId":"NCT07109375","phase":"","title":"Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Italia","startDate":"2026-04","conditions":["Fabry Disease"],"enrollment":75,"completionDate":"2028-12"},{"nctId":"NCT05843916","phase":"PHASE3","title":"Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease","status":"COMPLETED","sponsor":"Bio Sidus SA","startDate":"2022-12-13","conditions":["Fabry Disease"],"enrollment":20,"completionDate":"2025-03-31"},{"nctId":"NCT02956954","phase":"NA","title":"Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-03-25","conditions":["Anderson-Fabry Disease"],"enrollment":26,"completionDate":"2023-01-23"},{"nctId":"NCT04281537","phase":"","title":"A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2020-03-01","conditions":["Fabry Disease"],"enrollment":82,"completionDate":"2022-05-18"},{"nctId":"NCT03614234","phase":"PHASE3","title":"Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-11-13","conditions":["Fabry Disease"],"enrollment":29,"completionDate":"2026-06-30"},{"nctId":"NCT07187440","phase":"","title":"A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-11-01","conditions":["Fabry Disease"],"enrollment":200,"completionDate":"2028-11-30"},{"nctId":"NCT06880250","phase":"","title":"Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry Disease","status":"ENROLLING_BY_INVITATION","sponsor":"NPO Petrovax","startDate":"2025-03-24","conditions":["Fabry Disease"],"enrollment":100,"completionDate":"2027-01"},{"nctId":"NCT07277361","phase":"","title":"Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment","status":"RECRUITING","sponsor":"Wladimir MAUHIN, Dr","startDate":"2024-10-08","conditions":["Fabry Disease","Aged 65 Years or Older","Alpha Galactosidase A Deficiency","Galactosidase A Gene Mutation"],"enrollment":100,"completionDate":"2031-10-14"},{"nctId":"NCT07235709","phase":"","title":"Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2025-11-12","conditions":["Fabry Disease"],"enrollment":25,"completionDate":"2029-11"},{"nctId":"NCT05067868","phase":"PHASE4","title":"A Study of Replagal in Children and Adults With Fabry Disease in India","status":"RECRUITING","sponsor":"Shire","startDate":"2022-11-01","conditions":["Fabry Disease"],"enrollment":5,"completionDate":"2026-11-30"},{"nctId":"NCT05039866","phase":"","title":"Long-Term Follow-up of Subjects Who Were Treated With ST-920","status":"ENROLLING_BY_INVITATION","sponsor":"Sangamo Therapeutics","startDate":"2021-08-16","conditions":["Fabry Disease","Fabry Disease, Cardiac Variant"],"enrollment":48,"completionDate":"2039-03"},{"nctId":"NCT06869499","phase":"NA","title":"Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Wladimir MAUHIN, Dr","startDate":"2025-05","conditions":["Splenomegaly","Splenectomy","Thrombopenia","Interstitial Lung Disease (ILD)","Hypocholesterolemia"],"enrollment":200,"completionDate":"2029-03-01"},{"nctId":"NCT04046224","phase":"PHASE1,PHASE2","title":"Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)","status":"COMPLETED","sponsor":"Sangamo Therapeutics","startDate":"2019-07-23","conditions":["Fabry Disease"],"enrollment":33,"completionDate":"2025-04-10"},{"nctId":"NCT06052800","phase":"","title":"Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-09-13","conditions":["Fabry Disease"],"enrollment":78,"completionDate":"2026-09-10"},{"nctId":"NCT06630312","phase":"EARLY_PHASE1","title":"Glycemic Response of Whole Beans and Bean Products","status":"COMPLETED","sponsor":"Iowa State University","startDate":"2023-03-28","conditions":["Healthy","Body Mass Index, Normal","Postprandial Hyperglycemia"],"enrollment":21,"completionDate":"2023-10-17"},{"nctId":"NCT04974749","phase":"PHASE3","title":"A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-05-01","conditions":["Fabry Disease"],"enrollment":20,"completionDate":"2024-01-03"},{"nctId":"NCT04840667","phase":"PHASE3","title":"A Study of Replagal in Treatment-naïve Adults With Fabry Disease","status":"TERMINATED","sponsor":"Shire","startDate":"2021-12-28","conditions":["Fabry Disease"],"enrollment":17,"completionDate":"2022-12-16"},{"nctId":"NCT04943991","phase":"NA","title":"Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wuerzburg University Hospital","startDate":"2021-07-01","conditions":["Fabry Disease","Fabry Disease, Cardiac Variant","Lysosomal Storage Diseases","HCM - Hypertrophic Cardiomyopathy","Anderson Fabry Disease"],"enrollment":200,"completionDate":"2024-10-01"},{"nctId":"NCT02800070","phase":"PHASE1","title":"Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-07","conditions":["Fabry Disease"],"enrollment":5,"completionDate":"2024-04"},{"nctId":"NCT00230607","phase":"PHASE4","title":"Study of the Effects of Fabrazyme Treatment on Lactation and Infants","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-05-28","conditions":["Fabry Disease","Alpha Galactosidase A Deficiency"],"enrollment":7,"completionDate":"2024-02-09"},{"nctId":"NCT01374997","phase":"NA","title":"Detection of Fabry Disease in Chronic Renal Failure Patients in Area Provence - Alpes - Côte d'Azur","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2011-06","conditions":["Fabry Disease"],"enrollment":6,"completionDate":"2013-05-14"},{"nctId":"NCT01981720","phase":"PHASE1,PHASE2","title":"Extension Study of PRX-102 for up to 60 Months","status":"COMPLETED","sponsor":"Protalix","startDate":"2014-01-16","conditions":["Fabry Disease"],"enrollment":15,"completionDate":"2021-11-09"},{"nctId":"NCT02795676","phase":"PHASE3","title":"Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function","status":"COMPLETED","sponsor":"Protalix","startDate":"2016-06","conditions":["Fabry Disease"],"enrollment":78,"completionDate":"2022-07"},{"nctId":"NCT01678898","phase":"PHASE1,PHASE2","title":"Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients","status":"COMPLETED","sponsor":"Protalix","startDate":"2012-10","conditions":["Fabry Disease"],"enrollment":18,"completionDate":"2016-03-06"},{"nctId":"NCT03018730","phase":"PHASE3","title":"Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)","status":"COMPLETED","sponsor":"Protalix","startDate":"2017-05-17","conditions":["Fabry Disease"],"enrollment":22,"completionDate":"2020-01-09"},{"nctId":"NCT03180840","phase":"PHASE3","title":"Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks","status":"COMPLETED","sponsor":"Protalix","startDate":"2017-07-10","conditions":["Fabry Disease"],"enrollment":30,"completionDate":"2020-08-01"},{"nctId":"NCT04143958","phase":"PHASE4","title":"To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease","status":"WITHDRAWN","sponsor":"Sanofi","startDate":"2020-09","conditions":["Fabry Disease"],"enrollment":0,"completionDate":"2023-11"},{"nctId":"NCT05520411","phase":"NA","title":"Examining the Effectiveness of Digestive Enzymes at Reducing Bloating and Stomach Distension","status":"COMPLETED","sponsor":"HUM Nutrition, Inc.","startDate":"2022-07-01","conditions":["Stomach Distended","Bloating"],"enrollment":25,"completionDate":"2023-01-15"},{"nctId":"NCT04965467","phase":"","title":"Fabry Aim Children Early (ACE) Project","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2021-07-27","conditions":["Fabry Disease"],"enrollment":0,"completionDate":"2022-02-28"},{"nctId":"NCT00084084","phase":"PHASE2","title":"Replagal Enzyme Replacement Therapy for Children With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2004-06-10","conditions":["Fabry Disease"],"enrollment":17,"completionDate":"2011-06-15"},{"nctId":"NCT01304277","phase":"PHASE2","title":"This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.","status":"COMPLETED","sponsor":"Shire","startDate":"2011-11-17","conditions":["Fabry Disease"],"enrollment":17,"completionDate":"2012-12-28"},{"nctId":"NCT03230591","phase":"","title":"Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2017-07-12","conditions":["Fabry Disease"],"enrollment":25,"completionDate":"2025-01"},{"nctId":"NCT00864851","phase":"PHASE3","title":"Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2008-12-29","conditions":["Fabry Disease"],"enrollment":44,"completionDate":"2012-07-05"},{"nctId":"NCT01363492","phase":"PHASE2","title":"Safety Study of Replagal® Therapy in Children With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2011-05-12","conditions":["Fabry Disease"],"enrollment":15,"completionDate":"2013-04-17"},{"nctId":"NCT01124643","phase":"PHASE3","title":"Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2010-04-13","conditions":["Fabry Disease"],"enrollment":35,"completionDate":"2013-07-08"},{"nctId":"NCT01298141","phase":"PHASE3","title":"A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2011-08-10","conditions":["Fabry Disease"],"enrollment":171,"completionDate":"2017-09-25"},{"nctId":"NCT01031173","phase":"","title":"Treatment Protocol of Replagal for Patients With Fabry Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Shire","startDate":"","conditions":["Fabry Disease"],"enrollment":0,"completionDate":""},{"nctId":"NCT01268241","phase":"","title":"The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease","status":"COMPLETED","sponsor":"CENTOGENE GmbH Rostock","startDate":"2010-12","conditions":["Fabry Disease","Fabry´s Disease","Anderson-Fabry Disease"],"enrollment":200,"completionDate":"2016-04"},{"nctId":"NCT01355146","phase":"","title":"Home Therapy With Replagal in Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2011-03-15","conditions":["Fabry Disease"],"enrollment":127,"completionDate":"2017-09-30"},{"nctId":"NCT01196871","phase":"PHASE2","title":"Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2011-02-02","conditions":["Fabry Disease"],"enrollment":20,"completionDate":"2012-10-09"},{"nctId":"NCT01218659","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2011-09-08","conditions":["Fabry Disease"],"enrollment":68,"completionDate":"2015-05-28"},{"nctId":"NCT02969200","phase":"","title":"Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance","status":"COMPLETED","sponsor":"Ulla Feldt-Rasmussen","startDate":"2015-04","conditions":["Fabry Disease"],"enrollment":52,"completionDate":"2016-12-09"},{"nctId":"NCT02908724","phase":"","title":"Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement Therapy","status":"COMPLETED","sponsor":"Ulla Feldt-Rasmussen","startDate":"2014-11","conditions":["Fabry Disease"],"enrollment":66,"completionDate":"2016-02-09"},{"nctId":"NCT03596398","phase":"","title":"Epidemiological Study of Fabry Disease in Taiwan Young Stroke Patients","status":"UNKNOWN","sponsor":"Chiayi Christian Hospital","startDate":"2016-01-01","conditions":["Fabry Disease"],"enrollment":1000,"completionDate":"2022-01-31"},{"nctId":"NCT02930655","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2015-02-01","conditions":["Fabry Disease"],"enrollment":14,"completionDate":"2016-02-01"},{"nctId":"NCT01019629","phase":"","title":"Fabry Screening Study","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2009-01-29","conditions":["Fabry Disease"],"enrollment":2724,"completionDate":"2017-12-07"},{"nctId":"NCT02921620","phase":"PHASE3","title":"Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease","status":"WITHDRAWN","sponsor":"Protalix","startDate":"2017-07","conditions":["Fabry Disease"],"enrollment":0,"completionDate":"2018-07"},{"nctId":"NCT02995993","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Greenovation Biotech GmbH","startDate":"2016-11","conditions":["Fabry Disease"],"enrollment":6,"completionDate":"2017-10-09"},{"nctId":"NCT00106912","phase":"","title":"Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2005-03-28","conditions":["Fabry Disease"],"enrollment":35,"completionDate":"2008-03-27"},{"nctId":"NCT00001491","phase":"","title":"Analysis of the Nervous System in Patients With Fabry's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1995-05-11","conditions":["Fabry's Disease"],"enrollment":325,"completionDate":"2008-03-03"},{"nctId":"NCT02649660","phase":"","title":"Lipidomics and Functional Analyses of Platelets in Fabry Disease","status":"UNKNOWN","sponsor":"Spital Linth","startDate":"2015-10","conditions":["Fabry Disease"],"enrollment":32,"completionDate":"2017-12-31"},{"nctId":"NCT01745185","phase":"","title":"Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta","status":"COMPLETED","sponsor":"O & O Alpan LLC","startDate":"2012-06","conditions":["Fabry Disease"],"enrollment":30,"completionDate":"2016-08-07"},{"nctId":"NCT02843334","phase":"","title":"Study of the Prevalence of Fabry Disease in French Dialysis Patients","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2016-05","conditions":["Fabry Disease","End Stage Renal Disease","Renal Dialysis"],"enrollment":6000,"completionDate":"2017-05"},{"nctId":"NCT01295008","phase":"","title":"Androgenetic Alopecia in Fabry Disease","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2010-12","conditions":["Fabry Disease"],"enrollment":107,"completionDate":"2015-10"},{"nctId":"NCT00196716","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2003-06","conditions":["Fabry Disease"],"enrollment":21,"completionDate":"2007-03"},{"nctId":"NCT00081497","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-01","conditions":["Fabry Disease"],"enrollment":67,"completionDate":"2005-09"},{"nctId":"NCT00068107","phase":"PHASE2","title":"Dosing Study of Replagal in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2003-09","conditions":["Fabry Disease"],"enrollment":13,"completionDate":"2013-12"},{"nctId":"NCT01483287","phase":"EARLY_PHASE1","title":"The Effects of Added Enzyme α-Galactosidase at a Carbohydrate-rich Meal in Irritable Bowel Syndrome (IBS)","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2011-11","conditions":["Irritable Bowel Syndrome"],"enrollment":20,"completionDate":"2013-08"},{"nctId":"NCT01997489","phase":"PHASE4","title":"Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2001-09","conditions":["Fabry Disease"],"enrollment":39,"completionDate":"2014-10"},{"nctId":"NCT01650779","phase":"PHASE4","title":"A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2012-04","conditions":["Fabry Disease"],"enrollment":15,"completionDate":"2013-03"},{"nctId":"NCT01632111","phase":"","title":"Pulmonary Involvement in Patients With Fabry Disease","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2012-07","conditions":["Fabry Disease"],"enrollment":110,"completionDate":"2014-05"},{"nctId":"NCT00312767","phase":"PHASE4","title":"A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.","status":"WITHDRAWN","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-04","conditions":["Fabry Disease"],"enrollment":0,"completionDate":""},{"nctId":"NCT01304875","phase":"","title":"Pulmonary Disease and Exercise Tolerance in Boys With Fabry Disease","status":"UNKNOWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2010-04","conditions":["Fabry Disease"],"enrollment":20,"completionDate":""},{"nctId":"NCT00357786","phase":"PHASE1","title":"An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-10","conditions":["Fabry Disease"],"enrollment":3,"completionDate":""},{"nctId":"NCT01243853","phase":"NA","title":"Alpha-galactosidase Enzyme and Irritable Bowel Syndrome","status":"UNKNOWN","sponsor":"Verman Oy Ab","startDate":"2010-12","conditions":["Irritable Bowel Syndrome"],"enrollment":150,"completionDate":"2012-02"},{"nctId":"NCT00881322","phase":"NA","title":"A Study on Intestinal Gas Symptoms to Evaluate the Effects of Gas Defense in Otherwise Healthy Adult","status":"COMPLETED","sponsor":"Miami Research Associates","startDate":"2008-06","conditions":["Abdominal Pain","Abdominal Cramps","Flatulence"],"enrollment":61,"completionDate":"2008-09"},{"nctId":"NCT00075244","phase":"PHASE2","title":"Alternative Dosing and Regimen of Replagal to Treat Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2004-01","conditions":["Fabry Disease"],"enrollment":25,"completionDate":"2005-11"},{"nctId":"NCT00048906","phase":"PHASE2","title":"Alpha-Galactosidase A Replacement Therapy for Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2002-11","conditions":["Fabry Disease"],"enrollment":3,"completionDate":"2003-11"},{"nctId":"NCT00071877","phase":"PHASE2","title":"An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-10","conditions":["Fabry Disease"],"enrollment":25,"completionDate":"2005-06"},{"nctId":"NCT00097890","phase":"PHASE4","title":"Replagal Enzyme Replacement Therapy for Adults With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2004-11","conditions":["Fabry Disease"],"enrollment":25,"completionDate":"2005-12"},{"nctId":"NCT00030134","phase":"","title":"Data Collection in Women With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2002-01","conditions":["Fabry Disease"],"enrollment":60,"completionDate":"2003-02"},{"nctId":"NCT00487630","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-06","conditions":["Fabry Disease"],"enrollment":34,"completionDate":"2009-06"}],"_emaApprovals":[{"date":"2001-08-03","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"008578","UNII":"2HLC17MX9G","INN_ID":"8048","UMLSCUI":"C0962517","chemblId":"CHEMBL2108214","ChEMBL_ID":"CHEMBL2108214","KEGG_DRUG":"D02784","DRUGBANK_ID":"DB15874","SNOMEDCT_US":"423634009","SECONDARY_CAS_RN":"104138-64-9","MESH_SUPPLEMENTAL_RECORD_UI":"C000627036"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":244,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A16AB03","allCodes":["A16AB03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"41607773","title":"A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease.","journal":"Frontiers in immunology"},{"date":"2025 Nov","pmid":"41377851","title":"Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis.","journal":"Clinical kidney journal"},{"date":"2026 Jan 21","pmid":"41313298","title":"Long-Term Cardiac Stability Despite Late Enzyme Replacement Therapy in Fabry Disease With Severe Renal Involvement.","journal":"JACC. Case reports"},{"date":"2026 Jan","pmid":"41196191","title":"Long-term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey.","journal":"European journal of clinical investigation"},{"date":"2025 Sep 26","pmid":"41013812","title":"Adequate hemodialysis does not compromise the cardioprotective effect of agalsidase alfa on patients with Fabry disease: a case report.","journal":"Journal of medical case reports"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Enzyme","firstApprovalDate":"2001","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":2},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:21:01.795330+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}